医学研究与教育 ›› 2020, Vol. 37 ›› Issue (4): 1-7.DOI: 10.3969/j.issn.1674-490X.2020.04.001

• 基础医学 •    下一篇

SIRT家族在缺血性脑卒中中作用的研究进展

河泰麟,庞涛   

  1. 中国药科大学药物科学研究院, 江苏 南京 210009
  • 收稿日期:2020-04-07 出版日期:2020-08-25 发布日期:2020-08-25
  • 通讯作者: 庞涛(1979—),男,江苏南京人,研究员,博士,博士生导师,主要从事心脑血管药理学研究。E-mail: tpang@cpu.edu.cn
  • 作者简介:河泰麟(1995—),男,辽宁沈阳人,在读硕士,主要从事心脑血管药理学研究。 E-mail: hetailin@126.com
  • 基金资助:
    中国药科大学“双一流”建设科技创新团队项目(CPU2018GY06)

  • Received:2020-04-07 Online:2020-08-25 Published:2020-08-25

摘要: 沉默调节蛋白(sirtuins,SIRT)家族是NAD+依赖性赖氨酸去乙酰化酶和ADP核糖转移酶的进化保守家族,调节细胞生理活性。NAD+水平在细胞生理活动中是动态变化的,NAD+的异常变化会引起各种疾病。SIRT在大脑中具有细胞特异性及细胞器特异性表达,参与多种疾病的发生,如缺血性脑卒中。因此,开发和使用SIRT特异性调节剂可以促进神经保护,有望成为治疗缺血性脑卒中的新靶点。

关键词: 缺血性脑卒中, 沉默调节蛋白, NAD+

Abstract: The SIRT family is an evolutionarily conserved family of NAD+-dependent lysine deacetylases and ADP ribose transferases that regulate cell physiological activity. NAD+ levels are dynamically changed in the physiological activities of cells, whose abnormal changes can cause various diseases. SIRT has cell-specific and organelle-specific expressions in the brain and is involved in the pathology of many diseases, including ischemic stroke. Therefore, the development and use of SIRT-specific modulators might exhibit neuroprotection effects and is expected to develop a new target for the treatment of ischemic stroke.

Key words: ischemic stroke, sirtuins, NAD+

中图分类号: